This review highlights the need for physician vigilance regarding the physiologic and non-physiologic side effects of ACE inhibitors, especially in patients with comorbid cardiac or renal conditions.
Answers are grounded in this paper and cite their sources.
Urges closer monitoring of ACE inhibitor side effects in cardiac/renal patients; leaves open need for prospective validation before practice change.
Angiotensin‐converting enzyme (ACE) inhibitors are increasingly recognized as having an important role in the treatment of hypertension and/or end‐organ disease. The sheer number of ACE inhibitors in the United States—now numbering 10 different chemical entities—has created a sense of comfort with these compounds, which is particularly evident when these compounds are used in the patient with essential hypertension; conversely, when comorbid conditions are present in the ACE inhibitor‐treated patient, circumstances change and physician vigilance becomes more of a necessity. ACE inhibitor therapy in patients with either cardiac and/or renal disease is as much an art as it is a science, and even in the most skilled hands can prove a challenging undertaking. This review discusses the physiologic and non‐physiologic basis for side effects with ACE inhibition.
No takes yet. Share an insight, caveat, or question.
Domenic A. Sica (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: